NCT07332000 2026-03-17
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Candel Therapeutics, Inc.
Phase 2 Recruiting
Clinical Trials
508 trialsNCT00417495 2026-03-16
IGASSU
Centre Oscar Lambret
Phase 2 Completed
NCT00904410 2026-03-13
CHIMTEP
Centre Oscar Lambret
Phase 4 Completed
NCT04300556 2026-03-13
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Phase 1/2 Recruiting
NCT04644770 2026-03-13
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05968326 2026-03-12
IMCODE003
Genentech, Inc.
Phase 2 Recruiting
NCT00923026 2026-03-11
Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
National Institutes of Health Clinical Center (CC)
Enrolling by invitation
NCT06901531 2026-03-11
LUCERNA
Astellas Pharma Inc
Phase 3 Recruiting
NCT06902545 2026-03-11
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
Astellas Pharma Inc
Recruiting
NCT07460726 2026-03-10
PRIAPUS-PCa
CancerCare Manitoba
Not yet recruiting
NCT06957691 2026-03-09
Fezo-ADT
Brigham and Women's Hospital
Phase 2 Recruiting
NCT07182279 2026-03-09
Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
The Methodist Hospital Research Institute
Phase 1/2 Recruiting
NCT00102544 2026-03-06
Use of Tracking Devices to Locate Abnormalities During Invasive Procedures
National Institutes of Health Clinical Center (CC)
Phase NA Enrolling by invitation
NCT07455422 2026-03-06
Endeavor-2
University Hospital, Antwerp
Phase NA Not yet recruiting
NCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT05672524 2026-03-04
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05873686 2026-03-03
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma, Inc.
Phase 1 Recruiting
NCT07444983 2026-03-03
Rezvilutamide for High-Risk Prostate Cancer After Surgery
Fujian Medical University Union Hospital
Phase NA Not yet recruiting
NCT05063565 2026-03-02
ROWAN
Boston Scientific Corporation
Phase 2 Active not recruiting
NCT07439913 2026-02-27
Predictive Factors for 10-year Biochemical Recurrence and Urinary Continence Following Robot-assisted Radical Prostatectomy for Prostate Cancer
F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica
Enrolling by invitation
NCT04605913 2026-02-25
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
Mayo Clinic
Phase 1/2 Recruiting
NCT05581121 2026-02-25
PAROLA
Institut Claudius Regaud
Phase 3 Recruiting
NCT06834204 2026-02-25
ACCESS-PC
Rutgers, The State University of New Jersey
Phase NA Not yet recruiting
NCT05014776 2026-02-24
Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT07124000 2026-02-24
DP-04
AstraZeneca
Recruiting
NCT07431281 2026-02-24
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT04379596 2026-02-23
DG-03
AstraZeneca
Phase 2 Recruiting
NCT07426055 2026-02-23
PRO-BOOST-LC
Affidea Nu-med Center of Oncological DIagnostics and Therapy
Phase 2/3 Not yet recruiting
NCT07259317 2026-02-20
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Corcept Therapeutics
Phase 2 Recruiting
NCT05922930 2026-02-19
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT06616597 2026-02-19
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT07417475 2026-02-18
Robot-Assisted Radical Prostatectomy: the HOOD Technique Versus Standard Anterior Reconstruction
Ankara University
Phase NA Completed
NCT07115914 2026-02-17
PSMA PET for Surveillance After Focal Therapy
University of Chicago
Phase NA Recruiting
NCT07413120 2026-02-17
Efficacy and Safety of VasoClip® vs. WeckClip® for Robotic Urologic Surgery
Incheon St.Mary's Hospital
Phase 3 Completed
NCT03504397 2026-02-13
Spotlight
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT07407608 2026-02-12
ABRUPT 2
University of Milano Bicocca
Recruiting
NCT07023315 2026-02-11
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Akeso
Phase 3 Recruiting
NCT00349830 2026-02-10
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
Stanford University
Recruiting
NCT06834152 2026-02-09
X-SMILE
University of Zurich
Recruiting
NCT07196488 2026-02-09
Dyadic Co-learning Intervention for Patients With Prostate Cancer and Their Spouses
National Taipei University of Nursing and Health Sciences
Phase NA Recruiting
NCT03653507 2026-02-06
GLOW
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT06631521 2026-02-05
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
AdventHealth
Phase 1 Recruiting
NCT07385703 2026-02-04
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Not yet recruiting
NCT03323944 2026-01-30
CAR T Cell Immunotherapy for Pancreatic Cancer
University of Pennsylvania
Phase 1 Terminated
NCT06693128 2026-01-28
Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer
Ruijin Hospital
Phase 2 Active not recruiting
NCT06564844 2026-01-27
TROPION-Lung12
AstraZeneca
Phase 3 Active not recruiting
NCT07368985 2026-01-27
Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer
Erasmus Medical Center
Phase 2 Not yet recruiting
NCT07370597 2026-01-27
LUDOPATH
Jules Bordet Institute
Recruiting
NCT04208347 2026-01-23
Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
Ruijin Hospital
Phase 2/3 Active not recruiting
NCT07363382 2026-01-23
The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer
First Affiliated Hospital of Fujian Medical University
Phase 1/2 Recruiting